IR Licensing and Partnerships

How the Metsera deal extends Pfizer’s 25-year blueprint for growth.

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to advance RNAi-based treatments for metabolic diseases, with the agreements collectively valued at more than $1.6 billion in potential milestone payments.

Following Pfizer's lawsuits, Novo Nordisk enhanced its acquisition offer for Metsera, resulting in Pfizer also sending an enhanced offer.

Boehringer Ingelheim and Merck focus on innovative biologic and oncology advancements, driving collaborative growth through new R&D funding, and development and commercialization agreements.

Pharmaceutical collaborations thrive as Manifold Bio, 4DMT, and Kaigene forge strategic partnerships to advance innovative therapies for neurological and autoimmune diseases.

GSK secures exclusive rights to EMP-012, a promising treatment for COPD, enhancing its respiratory pipeline and addressing unmet medical needs.

GSK secures exclusive rights to Syndivia's promising ADC for metastatic castration-resistant prostate cancer, enhancing treatment options for patients.

Novartis acquires Avidity Biosciences to enhance its RNA therapeutics pipeline, targeting rare neuromuscular diseases with innovative therapies.

Eli Lilly plans to acquire Adverum Biotechnologies for $3.56 per share, enhancing its portfolio in innovative genetic medicines for vision restoration.

The acquisition aims to enhance Alkermes' entry into the sleep medicine market and expanding its product portfolio.

The collaboration will focus on enhancing cancer therapies through next-gen immuno-oncology and ADC treatments for solid tumors.

EMD Serono partners with the U.S. government to enhance IVF access, offering significant discounts on fertility treatments for millions of women.

Pharmaceutical companies enhance cancer and autoimmune disease treatments through strategic collaborations, advancing innovative therapies, and improving patient outcomes.

The biopharmaceutical sector sees major acquisitions, enhancing capabilities in RNA therapies and rare diseases, with key players like BioCryst and Bristol Myers Squibb leading the charge.

Nabla Bio and Takeda enhance their partnership to revolutionize AI-driven protein therapeutics, aiming for groundbreaking advancements in drug development.

Bristol Myers Squibb acquires Orbital Therapeutics to enhance its CAR T-cell therapy portfolio, promising innovative treatments for autoimmune diseases.

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 billion, in addition to single-digit royalties.

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine for potential distribution in low- and middle-income countries.

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients with atrial fibrillation and cancer-associated thrombosis.

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung cancer who are PD-1 checkpoint inhibitor resistant.